This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B24 (Unspecified human immunodeficiency virus disease) | Special Copayment Reduction: V103 (severe intractable disease, 5 years) |
| B. Synonyms | Acquired immunodeficiency syndrome NOS; AIDS-related complex NOS; AIDS NOS; Acquired immunodeficiency syndrome unspecified; HIV disease NOS |
| C. Adult onset | Likelihood of adult onset: very high — B24 is a residual (NOS, Not Otherwise Specified) code used when HIV disease (including AIDS) due to HIV infection has been confirmed but no specific opportunistic infection, malignancy, or other specific complication is specified or can be classified. It is mainly applied to incomplete death certificates, epidemiologic reports, and clinical records. |
| 1. History | After the CDC's first description of AIDS in 1981, the concept of "acquired immunodeficiency syndrome" was established. AIDS NOS is an epidemiologic and statistical code covering cases diagnosed only as an AIDS state without specification of a specific complication. The context of use of the B24 code has changed along with the changing epidemiology of HIV/AIDS. |
| 2. Causes | HIV-1 or HIV-2 infection. Sexual transmission (anal, vaginal, oral intercourse), blood exposure (injection drugs, transfusion), vertical transmission (mother to child). Immunosuppression due to HIV infection leads to various AIDS complications. AIDS state without specification of a specific complication. |
| 3. Genetics | Not a hereditary disease. Host genetic factors (HLA, CCR5, CCR2 polymorphisms) influence susceptibility to HIV infection, immune progression, and development of specific complications. When classified as B24, no specific complication is specified, so the genetic association is not specifically determined by the code itself. |
| 4. General epidemiology | Cumulative HIV infections worldwide about 84 million, AIDS deaths about 40 million (UNAIDS, 2023). In 2022, about 39 million people worldwide were living with HIV. Korea: about 1,000 new HIV diagnoses in 2023, cumulative total of about 25,000 or more. B24 is widely used as a classification code for statistical and epidemiologic purposes. |
| 5. Pathophysiology | HIV infection → progressive loss of CD4+ T cells → immunodeficiency → development of AIDS-defining complications. Because B24 covers AIDS states without specification of a specific complication, the pathophysiology is based on the general course of HIV immune depletion. |
| 6. Symptoms | Symptoms of AIDS NOS are nonspecific because no specific complication is specified. General AIDS-related symptoms: fever, night sweats, weight loss, fatigue, lymphadenopathy. Symptoms of opportunistic infection or tumor may accompany, but the condition is unspecified. |
| 7. Signs | Immunodeficiency confirmed with CD4 <200/μL. HIV RNA positive. B symptoms (fever, night sweats, weight loss of 10% or more within 6 months). General clinical AIDS state without specification of a specific complication. |
| 8. Screening | Expanding access to HIV testing is key. Regular HIV antibody testing in high-risk groups (MSM, intravenous drug users, sex workers). Minimizing the window period with 4th-generation HIV Ag/Ab testing. Prospective HIV testing in healthcare institutions is recommended. |
| 9. Diagnosis | B24 is used when HIV infection has been confirmed but a specific AIDS complication code (B20-B23.8) cannot be assigned. HIV diagnosis: confirmation of a positive HIV antibody test (4th-generation Ag/Ab) + HIV RNA PCR. CDC 1993 AIDS definition: CD4 <200/μL or presence of an AIDS-defining illness. |
| 10. Treatment | Immediate initiation of ART in all people with HIV. Standard first-line ART: INSTI-based (BIC/TAF/FTC or DTG + TDF/FTC). Opportunistic infection prophylaxis (by CD4 level). Assessment of ART response (regular monitoring of HIV RNA and CD4). When a complication is specified, switch to the corresponding code and add specific treatment. |
| 11. Prognosis | In the ART era, the life expectancy of patients with HIV/AIDS approaches that of the general population. Near-normal life expectancy can be expected with early diagnosis and treatment. The median survival of AIDS patients not treated with ART is about 2-3 years after AIDS diagnosis. For prognosis, the timing of ART initiation, baseline CD4, and adherence are the most important. |
| 12. Prevention | HIV prevention: safe sexual practices (condoms), PrEP (pre-exposure prophylaxis), PEP (post-exposure prophylaxis), clean injection equipment. AIDS prevention: early HIV diagnosis and immediate ART (U=U principle). Prevention of mother-to-child transmission (PMTCT). Reducing HIV stigma and expanding access to testing. |
| 13. References | Includes 10 key references |
The history of acquired immunodeficiency syndrome (AIDS) began on June 5, 1981, when the US CDC's Morbidity and Mortality Weekly Report (MMWR) reported a cluster of Pneumocystis pneumonia (PCP) and Kaposi sarcoma in 5 homosexual men in Los Angeles. This was the official beginning of the HIV/AIDS epidemic that changed the world.
In 1982, the CDC named this new immunodeficiency disease "acquired immunodeficiency syndrome (AIDS)." At that time the causative agent was unknown, and it was called the "4H disease" because it occurred in homosexuals, hemophiliacs, injection drug users, and immigrants from Haiti. In 1983, Luc Montagnier and colleagues at the Pasteur Institute in France and Robert Gallo and colleagues at the US NCI independently isolated the retrovirus that causes AIDS, and in 1986 the official name HIV (Human Immunodeficiency Virus) was adopted.
In 1987, zidovudine (AZT), the first anti-HIV drug, received FDA approval and began to be used clinically. However, as monotherapy, resistance developed quickly and its effect was limited. With the introduction of protease inhibitors (PIs) in 1995-1996 and the establishment of highly active antiretroviral therapy (HAART, now ART), combining three or more drugs, the clinical picture of HIV/AIDS changed fundamentally.
After the introduction of ART, AIDS mortality dropped sharply and HIV infection was redefined as a "chronic manageable disease." AIDS was no longer a "death sentence" but a disease in which near-normal life expectancy can be expected with early diagnosis and ART. At the same time, chronic non-AIDS complications (cardiovascular, renal, neurocognitive, osteoporosis), a new challenge of the ART era, have emerged.
In Korea, new infections have continued to occur since the first HIV-infected person was reported in 1985. The Korea Disease Control and Prevention Agency (KDCA) publishes HIV/AIDS statistics every year, and as of 2023 the number of new HIV infections per year is about 1,000. In Korea, HIV infection is managed under the Prevention of Acquired Immunodeficiency Syndrome Act, and medical expenses are supported through Special Copayment Reduction (V103).
The ICD-10 code B24 is "Unspecified human immunodeficiency virus disease (AIDS NOS, AIDS-related complex NOS)" and covers HIV/AIDS states that cannot be classified under the specific codes B20-B23.8. It is mainly used when death certificates, epidemiologic databases, and clinical records are incomplete, and is an important code category in global HIV/AIDS epidemiologic statistics.
The cause of unspecified HIV disease classified as B24 is HIV infection itself. This is the case when HIV/AIDS has been confirmed without the cause of a specific complication being separately specified.
Types and characteristics of HIV: HIV-1 is the main cause, accounting for 99% of AIDS worldwide. Among HIV-1, group M (main group) is the most common, and group M contains subtypes A-K. Subtype B predominates in Western Europe and North America, and subtype C is the most common in Africa (especially southeastern Africa) and Asia. Group O (outlier) and group N appear rarely in west-central Africa such as Cameroon. HIV-2 occurs mainly in West Africa, has lower virulence than HIV-1, and AIDS progresses more slowly.
Routes of transmission: Sexual transmission: anal intercourse (most efficient, especially for the receptive partner), vaginal intercourse, rarely oral intercourse. Blood transmission: shared injection needles, contaminated blood products (now very rare in developed countries owing to secured transfusion safety), medical accidents. Vertical transmission: across the placenta during pregnancy (15-40%), during delivery (45-65%), breastfeeding (14%). With PMTCT (prevention of mother-to-child transmission) programs, the vertical transmission rate falls to <2%.
HIV replication and immune destruction: HIV is an RNA virus that integrates viral DNA (proviral DNA) into host cell DNA using reverse transcriptase, establishing a permanent latent infection. Sustained loss of CD4+ T cells is the core pathology of AIDS, and a decline of about 50-100 CD4/μL per year is observed in patients not treated with ART. At CD4 <200/μL, the risk of opportunistic infection rises sharply and AIDS manifests.
Situations in which the B24 code applies: (1) HIV infection has been confirmed but diagnostic testing for a specific AIDS-defining complication has not been performed; (2) the death certificate states only "AIDS"; (3) a specific complication code cannot be assigned in an epidemiologic database; (4) the patient is clinically at the AIDS stage but a specific complication has not yet been identified.
Unspecified HIV disease classified as B24 is not itself a hereditary disease. However, host genetic factors play an important role throughout the clinical course of HIV infection.
Genes for resistance to HIV infection: CCR5-Δ32 homozygotes (about 1%, of Northern European descent): complete resistance to R5 HIV. As a clinical application of this genotype, Timothy Ray Brown (the "Berlin patient") received a bone marrow transplant from a CCR5-Δ32 homozygous donor and became the first case of successful functional cure of HIV. TRIM5α polymorphism: differences in ability to inhibit HIV reverse transcription. APOBEC3G/H polymorphism: differences in innate immune function that inhibits HIV replication.
Genes determining the rate of HIV progression: HLA-B*57:01, B*57:03, B*27:05: enhanced HIV-specific CD8+ CTL response, slow AIDS progression. A considerable proportion of long-term nonprogressors (LTNP) carry these HLA alleles. HLA-B*35:01, B*35:03: associated with rapid AIDS progression. CCR5-Δ32 heterozygotes: AIDS progression delayed by about 2 years. CCR2-64I polymorphism: AIDS progression delayed by about 2 years (CCR2 limits CCR5 co-receptor function).
Genes for susceptibility to specific complications: APOL1 G1/G2: greatly increased risk of HIVAN. FCGR3A polymorphism: susceptibility to cryptococcal meningitis. MBL2 polymorphism: determines mannose-binding lectin level, susceptibility to PCP and bacterial infection. HLA-B*57:01: predictive marker for abacavir hypersensitivity reaction.
Genetic diversity of HIV itself: The high mutation rate of HIV (no proofreading by reverse transcriptase) creates genetic diversity within the virus. This diversity is the basis for the development of ART resistance, immune evasion, and differences in virulence. HIV quasispecies concept: various HIV variant strains coexist within a single infected person.
HIV/AIDS is one of the most important infectious disease epidemics from the end of the 20th century into the 21st century.
Global epidemiology: According to the UNAIDS 2023 report, about 39 million people worldwide are living with HIV. The number of new HIV infections in 2022 was about 1.3 million (a 41% decrease from 2.2 million in 2010). The number of AIDS-related deaths in 2022 was about 630,000 (a 68% decrease from the peak of about 2 million in 2004). Sub-Saharan Africa accounts for about 65% of people with HIV worldwide. Men who have sex with men (MSM), sex workers, intravenous drug users, and transgender women are the main vulnerable groups.
Epidemiology in Korea: Since the first HIV-infected person was reported in Korea in 1985, new infections have occurred steadily every year. According to KDCA statistics, there were about 1,000 new HIV infections in 2023, and the cumulative number of reported HIV cases is about 25,000 or more. About 90% of new infections are in men, and MSM (men who have sex with men) is the main route of infection. New infections are concentrated in young adult men in their 20s and 30s. Viral suppression is achieved in about 95% of people with HIV receiving ART, and treatment outcomes are excellent.
Epidemiologic use of the B24 code: B24 is used to classify AIDS cases without a specified complication in death certificates, hospital administrative databases, and national AIDS surveillance statistics. In low-income countries, the proportion of B24 code use may be high owing to limited diagnostic capacity. In Korea, the B24 code is mainly used to record the general HIV infection state after HIV confirmation and before a specific AIDS complication develops.
AIDS definition and epidemiologic significance: CDC 1993 AIDS definition: (1) HIV infection + CD4 <200/μL (absolute count), or (2) HIV infection + one of 26 AIDS-defining clinical conditions. WHO clinical stage IV: end-stage HIV disease (various AIDS-defining complications). Korean AIDS surveillance criteria: the 1993 CDC criteria are applied mutatis mutandis.
The pathophysiology of unspecified HIV disease classified as B24 is based on the general course of HIV infection and reflects the immune pathology of an AIDS state in which no specific complication is specified.
Natural history of HIV infection: HIV infection progresses through four stages: (1) acute HIV infection syndrome (B23.0), (2) clinical latency (asymptomatic chronic infection), (3) early symptomatic HIV infection (persistent generalized lymphadenopathy, PGL), and (4) AIDS. In patients not treated with ART, AIDS manifests after a latency period of about 10 years on average after infection. Each stage is determined by the CD4 level and the HIV viral load (set-point viral load).
Mechanisms of CD4+ T cell loss: Direct cell destruction by HIV: syncytium formation, induction of apoptosis. Immune-mediated destruction: CD8+ CTL response against HIV-infected CD4+ T cells. Activation-induced cell death (AICD): depletion of CD4+ T cells by chronic immune stimulation. Reduced regenerative capacity: decreased thymic function (especially in the elderly) reduces CD4 replenishment. The rapid loss of CD4 memory T cells in the gut mucosa is the starting point of chronic immune activation.
Pathophysiology of AIDS manifestation: At CD4 <200/μL, defense mechanisms against opportunistic infections collapse. Reduced Th1 immune response (defense against intracellular pathogens) leaves patients vulnerable to Mycobacterium tuberculosis, Toxoplasma, PCP, and Leishmania. The relative predominance of the Th2 immune response leaves them vulnerable to some parasitic infections. Reduced B cell function (functional hypergammaglobulinemia) increases infections with encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae). Reduced NK cell function makes it difficult to eliminate virus-infected cells (EBV, CMV, HHV-8).
Role of chronic immune activation: The most important predictor of AIDS progression in HIV infection is not only the CD4 count but also the level of chronic immune activation. The higher the serum CD8+ T cell activation markers (CD38, HLA-DR), interleukin-6, sCD14, and CRP, the greater the risk of AIDS progression and non-AIDS complications (cardiovascular, renal, neurocognitive). Suppression of HIV RNA by ART reduces immune activation, but complete normalization is difficult.
The clinical symptoms of B24 (unspecified HIV disease/AIDS NOS) encompass a broad range of HIV/AIDS-related symptoms without a specific AIDS complication specified.
B symptoms (systemic symptoms suggestive of AIDS): Persistent or recurrent fever (38℃ or higher, for 1 month or more), night sweats, and unintentional weight loss of 10% or more within 6 months are the typical systemic symptoms of AIDS. These B symptoms reflect opportunistic infection, malignancy, or systemic immune activation by HIV itself. Extreme fatigue, generalized weakness, and anorexia accompany them.
Recurrent infections due to immunodeficiency: Recurrent bacterial pneumonia, skin infections (cellulitis, impetigo). Recurrent herpes zoster or disseminated herpes zoster. Recurrent oral candidiasis or esophageal candidiasis. Generalized cutaneous mycoses (dermatophytes, Pityrosporum). Extensive, recurrent lesions of herpes simplex virus (HSV).
Other systemic symptoms: Persistent diarrhea (of unknown cause), abdominal pain, nausea. Cognitive decline, decreased concentration (mild HAND). Skin abnormalities (seborrheic dermatitis, worsening psoriasis, drug eruption). Sudden changes in the size of lymph node enlargement.
Asymptomatic HIV infection: Many people with HIV, especially patients on ART, are virtually asymptomatic. The B24 code may also apply to such virally suppressed people with HIV on ART. Even if asymptomatic, if HIV infection itself (Special Copayment Reduction V103) is confirmed, it can be classified as B24.
The clinical signs of patients classified as B24 vary according to the clinical stage of HIV infection and the complications that develop.
Immunologic signs: Decreased CD4+ T cell count: AIDS-defining immunodeficiency (CD4 <200/μL) or varying degrees of decrease. Inverted CD4/CD8 ratio (<0.5). HIV RNA positive (quantitative). Elevated β₂-microglobulin, sCD14, and CRP (immune activation markers).
Hematologic signs: Anemia (normocytic or macrocytic), lymphopenia, thrombocytopenia. Hyperimmunoglobulinemia (elevated IgG, IgA, IgM). Elevated LDH and uric acid are possible (reflecting tissue catabolism).
Systemic signs: Underweight (BMI <18.5), muscle wasting. Generalized lymph node enlargement (PGL pattern). Skin lesions (seborrheic dermatitis, psoriasis, herpes zoster scars). Oral lesions (candidiasis, hairy leukoplakia, aphthous ulcers).
Physical examination findings: When no specific complication is specified, nonspecific findings appear on physical examination. The combination of fever, weight loss, and lymphadenopathy is a finding suggestive of AIDS. Deterioration of general condition (decreased Karnofsky performance score) is observed.
Early detection of HIV is key to preventing AIDS, and an effective screening strategy is important.
General population screening: The CDC and WHO recommend HIV testing at least once in a lifetime for all adults aged 15-65. "Opt-out" HIV testing (performed automatically unless the person declines) is recommended at healthcare visits. Expanding access to voluntary HIV testing (self-test kits, anonymous testing centers).
Regular screening of high-risk groups: MSM: HIV testing every 3-6 months. Intravenous drug users: at least once a year. Sex workers: at least once a year. When there is a new sexual partner or a sexually transmitted infection is diagnosed: immediate HIV testing. People with an HIV-infected partner: at least once a year.
4th-generation HIV testing: The 4th-generation HIV-1/2 Ag/Ab combination test (p24 antigen + antibody) is the standard screening test. The window period is about 18-45 days, shorter than with 3rd-generation tests. A positive 4th-generation test is confirmed by an HIV-1/2 antibody differentiation test + HIV RNA PCR. The KDCA's HIV diagnostic algorithm in Korea also recommends 4th-generation testing.
Screening of pregnant women: HIV testing is performed in all pregnant women in early pregnancy (at the first prenatal visit). ART is started immediately in HIV-positive pregnant women to prevent mother-to-child vertical transmission. For newborns with HIV exposure, prophylactic ART and follow-up testing are performed.
The B24 code is used when HIV infection has been confirmed but a specific AIDS complication code (B20-B23.8) cannot be assigned.
Diagnosis of HIV infection: HIV infection is diagnosed according to the US CDC 2014 algorithm or WHO recommendations. (1) 4th-generation HIV-1/2 Ag/Ab combination test → if positive, (2) HIV-1/2 antibody differentiation test → if indeterminate or HIV-1 antibody negative, (3) HIV RNA PCR → if positive, HIV infection is confirmed. Positive Western blot: confirmation of HIV antibody.
Diagnosis of AIDS (CDC 1993 criteria): HIV infection + (1) CD4+ T cell count <200/μL (absolute count) or CD4 percentage <14%, or (2) one of 26 AIDS-defining clinical conditions (Pneumocystis pneumonia, Kaposi sarcoma, Kaposi sarcoma, CMV retinitis, toxoplasmosis, cryptococcal meningitis, disseminated MAC infection, recurrent pneumonia, cervical cancer, lymphoma, etc.). If an AIDS-defining clinical condition is present, AIDS is diagnosed regardless of CD4.
Criteria for applying the B24 code: When HIV infection is confirmed and AIDS is clinically suspected or diagnosed, but it is difficult to determine a specific AIDS-defining complication code. When the death certificate states only "AIDS" or "HIV infection." No specific complication information available when coding in an epidemiologic database. HIV/AIDS clinical states to which none of the codes B20-B23.8 applies.
Relationship of B24 to other codes: B24 is a "last resort" code that is less informative than any specific code in B20-B23.8. Using a more specific code in B20-B23.8 whenever possible improves the quality of clinical records and epidemiologic data. In Korean National Health Insurance claims, when Special Copayment Reduction (V103) is applied, all codes B20-B24, including B24, are eligible.
The treatment principle for HIV/AIDS patients classified as B24 is based on ART, which applies to all people with HIV.
Principle of immediate ART initiation: ART is started immediately in all people with HIV regardless of CD4 level or clinical stage (START study, 2015). Same-day start (rapid ART initiation) is recommended, which improves linkage to care and is advantageous for preserving early immune function. The WHO 2023 guidelines also recommend immediate ART for all people with HIV regardless of CD4 level.
Standard first-line ART (2024 DHHS/WHO criteria): An integrase strand transfer inhibitor (INSTI)-based three-drug combination regimen is the standard first line. Recommended regimens (listed in Korean alphabetical order): (1) bictegravir (BIC)/tenofovir alafenamide (TAF)/emtricitabine (FTC) — one tablet once daily, first-line recommendation; (2) dolutegravir (DTG)/abacavir (ABC)/lamivudine (3TC) — use after confirming HLA-B*57:01 negative; (3) dolutegravir (DTG) + tenofovir/emtricitabine (TDF/FTC or TAF/FTC). Two-drug regimen: DTG + lamivudine (DTG/3TC, Dovato®) — when baseline HIV RNA is <500,000 copies/mL and there is no HBV coinfection.
Status of ART treatment in Korea: People with HIV in Korea are managed at medical institutions designated by the KDCA (AIDS treatment hospitals). ART drugs are supported through National Health Insurance coverage and Special Copayment Reduction (V103). The ART viral suppression rate among people with HIV in Korea is about 95% or more, among the highest in the world. The domestic HIV treatment guidelines (published by the Korean Society for AIDS) are revised regularly to reflect the latest international standards.
Prevention and treatment of opportunistic infections: Prophylactic treatment by CD4 level: CD4 <200/μL: TMP-SMX (prevention of PCP and toxoplasmosis). CD4 <50/μL: azithromycin or clarithromycin (MAC prevention). Prophylactic treatment can be discontinued once the CD4 level recovers above the threshold and is maintained. When a specific opportunistic infection occurs, the standard treatment for that disease is applied and the code is changed to a more specific code in B20-B23.8.
ART monitoring: Measure HIV RNA at the first 4-8 weeks after starting ART and every 3-6 months thereafter. ART response goal: undetectable HIV RNA (<50 copies/mL). CD4 count: before starting ART, after 6 months, and 1-2 times a year thereafter. ART toxicity monitoring: regular measurement of kidney (creatinine, eGFR, urine protein), liver function, lipids, and blood glucose.
The prognosis of HIV/AIDS has improved dramatically since the introduction of ART, and people with HIV who receive early diagnosis and appropriate treatment can enjoy a life expectancy close to that of the general population.
Life expectancy in the ART era: In a UK cohort study (Survival of HIV-positive patients starting antiretroviral therapy study), the life expectancy of people diagnosed with HIV at age 20 in 2008-2010 who started ART immediately was 78 years, close to that of the general population (82 years). Main determinants of life expectancy: CD4 count at ART initiation (higher is better), ART adherence, smoking, comorbidities (HCV, cirrhosis, cardiovascular). Life expectancy is about 5-10 years shorter when ART is started at CD4 <200/μL than when started at CD4 >500/μL.
Prognosis of AIDS not treated with ART: When AIDS manifested without ART, the median survival was about 2-3 years (pre-ART cohort data). Prognosis improves greatly if ART is started immediately after an AIDS-defining opportunistic infection occurs. Some AIDS-defining diseases (cryptococcal meningitis, CMV retinitis, disseminated MAC infection) cause death within weeks to months if untreated.
Prognostic predictors: Good prognosis: high baseline CD4 count, early ART initiation, achievement of complete viral suppression with ART, high treatment adherence, non-smoking. Poor prognosis: low baseline CD4 count (<50/μL), delayed diagnosis, multidrug-resistant HIV, serious comorbidities (HCV cirrhosis, renal failure, advanced malignancy), ART nonadherence.
Non-AIDS complications and long-term prognosis: In the ART era, the main causes of death in people with HIV are shifting from AIDS complications to cardiovascular disease, malignancy, and liver disease. Chronic immune activation is the common basis of these non-AIDS complications. Early ART and active management of non-AIDS complications (smoking cessation, statins, blood pressure control) are key to improving long-term prognosis.
Prevention of HIV infection and prevention of AIDS manifestation are the two key prevention strategies.
Prevention of HIV infection (primary prevention): Condom use: correct condom use reduces sexual transmission of HIV by 85-95%. Pre-exposure prophylaxis (PrEP): tenofovir/emtricitabine (TDF/FTC or TAF/FTC) once daily prevents more than 99% of HIV infections in MSM and heterosexual high-risk groups. Injectable cabotegravir PrEP: an intramuscular injection once every 2 months has a prevention effect superior to oral PrEP. Post-exposure prophylaxis (PEP): ART for 28 days within 72 hours after high-risk HIV exposure. Needle exchange programs: reduce HIV transmission among intravenous drug users. Prevention of mother-to-child transmission (PMTCT): early ART initiation in HIV-positive pregnant women, choice of delivery method, prophylactic ART for newborns, suppression of breastfeeding (when alternatives are available).
Prevention of AIDS manifestation (secondary prevention): Early HIV diagnosis: get HIV testing at least once in a lifetime, and test immediately after high-risk behavior. Early ART: start ART immediately upon HIV confirmation to keep CD4 at a high level. Treatment as prevention (TasP): if HIV RNA is kept undetectable with ART, the virus is not transmitted to sexual partners (U=U principle). Prophylactic treatment of opportunistic infections: prophylactic antimicrobials such as TMP-SMX and azithromycin according to CD4 level.
National prevention policy in Korea: Reporting of HIV infection and epidemiologic investigation under the Prevention of Acquired Immunodeficiency Syndrome Act. Anonymous HIV testing services provided at public health centers and medical institutions. Access to treatment guaranteed through medical expense support for people with HIV (Special Copayment Reduction V103). HIV/AIDS prevention content included in school and workplace sex education. Public awareness campaigns to reduce HIV stigma.
Status of vaccine development: HIV vaccine development is very challenging because of the high genetic diversity of HIV, its immune evasion mechanisms, and the difficulty of inducing neutralizing antibodies. The RV144 Thailand trial (2009) is the only HIV vaccine clinical study to show a protective effect, of about 31%. mRNA-based and protein subunit HIV vaccines aimed at inducing broadly neutralizing antibodies (bNAbs) are currently in clinical trials. Research on functional cure, such as gene editing (CCR5 gene deletion) and CAR-T cell therapy, is also actively under way.